Introduction Painful bladder syndrome (PBS), also known as interstitial cystitis/bladder pain syndrome (IC/BPS), remains one of the most challenging chronic pelvic pain disorders to treat (1). The primary treatment goal is symptom relief, quality of life improvement, and prevention of flare-ups, as no therapy currently achieves complete remission (

Introduction Painful bladder syndrome, more commonly referred to today as interstitial cystitis / bladder pain syndrome (IC/BPS), is a chronic and heterogeneous disorder characterized by bladder, urethral, or pelvic pain accompanied by irritative urinary symptoms (frequency, urgency, nocturia) in the absence of infection or other identifiable cause

As artificial intelligence becomes a powerful force in modern medicine, one question stands out — how can it be used responsibly in clinical practice? Join us for an engaging session, where global leaders will share their perspectives on integrating AI ethically, effectively, and safely into day-to-day medical decision-making. Speakers: Dr Amit Kum

Introduction Genital reconstructive surgery, including phalloplasty, metoidioplasty, vaginoplasty, and urethral lengthening, has become increasingly refined within reconstructive urology and plastic surgery. These procedures aim to restore both urinary and sexual function while addressing aesthetic outcomes. However, they remain technically demandi

Definition and Scope Genitourinary Syndrome of Menopause (GSM) is a clinically recognized condition encompassing a spectrum of vulvovaginal and lower urinary tract symptoms caused by estrogen and androgen deficiency associated with menopause. Symptoms include: Vulvovaginal: Dryness, irritation, burning, pruritus, and dyspareunia Urinary: Urgency, f

Introduction Human papillomavirus (HPV) vaccination has been shown to significantly reduce the burden of HPV-related disease globally (1). Evidence from large-scale meta-analyses reveals dramatic declines in vaccine-type HPV infections among adolescent and young adult females (e.g., 83% reduction in ages 13–19 and 66% in ages 20–24) over 5–8 years

Introduction: Immunotherapy has emerged as an essential treatment option in advanced bladder cancer, offering survival benefits in patients who progress after platinum-based chemotherapy (1). Immune checkpoint inhibitors, including pembrolizumab, nivolumab, atezolizumab, and avelumab, have demonstrated durable responses and manageable safety profil

Introduction Urothelial carcinoma represents the most common form of bladder cancer and often presents at an advanced stage, where treatment outcomes remain poor despite initial responses to platinum-based chemotherapy (1). Historically, patients achieving disease control after chemotherapy had limited maintenance options, with observation being th

Introduction Complicated urinary tract infections (cUTIs) present significant challenges, often in patients with structural abnormalities, indwelling catheters, or comorbidities (1). The causative organisms extend beyond Escherichia coli to include klebsiella, Enterobacter, and Pseudomonas species, with multidrug resistance (MDR) limiting therapeut